Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study

Table 3

Summary of serious AEs in the safety population.

	LCIG n = 43	OMT n = 44
Any AE	36 (83.7)	21 (47.7)
Any serious AE	8 (18.6)	4 (9.1)
Treatment-emergent serious AEs
Pneumoperitoneum	2 (4.7)	0
Stoma site infection	2 (4.7)	0
Bacteremia	0	1 (2.3)
Urinary tract infection	0	1 (2.3)
Femur fracture	1 (2.3)	1 (2.3)
Parkinson’s disease	0	1 (2.3)
Fall	1 (2.3)	0
Lower limb fracture	1 (2.3)	0
Patella fracture	1 (2.3)	0
Subdural hematoma	1 (2.3)	0
Neuralgia	1 (2.3)	0
Depression	1 (2.3)	0

Data are reported as n (%). Patients are counted once in each row, regardless of the number of events they may have had. Abbreviations: AE: adverse event, LCIG: levodopa-carbidopa intestinal gel, and OMT: optimized medical treatment.